Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial - Takeaways - MDSpire

Efficacy and Safety of Deucravacitinib in Patients with Active Psoriatic Arthritis: Results from the Phase 3 POETYK PsA-2 Trial Over 52 Weeks

  • By

  • Philip J. Mease

  • Vinod Chandran

  • April W. Armstrong

  • Ricardo Blanco

  • Alexis Ogdie

  • Evan L. Siegel

  • Alice B. Gottlieb

  • Xiaofeng Zeng

  • Diamant Thaçi

  • Mitsumasa Kishimoto

  • Hendrik Schulze-Koops

  • Alan Kivitz

  • Eva Dokoupilová

  • Akimichi Morita

  • Eric M. Ruderman

  • Michael Plewinski

  • Kejia Wang

  • Caroline Sardinas

  • Eleni Vritzali

  • John Vaile

  • Atul Deodhar

  • July 20, 2026

Share

  • 1

    The POETYK PsA-2 trial evaluated deucravacitinib's efficacy and safety in active psoriatic arthritis over 52 weeks.

  • 2

    Patients in the trial were either naive to biologic DMARDs or had previously received TNF inhibitors.

  • 3

    The study was a randomized, double-blind, placebo-controlled trial with a 3:3:1 randomization ratio.

  • 4

    The primary endpoint was the ACR20 response at week 16, measuring 20% improvement in arthritis symptoms.

  • 5

    Patients receiving placebo could switch to deucravacitinib after week 16, continuing until week 52.

Original Source(s)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

  • by Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

  • July 20, 2026

Related Content

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

A clinical care pathway for managing pregnancy in patients with inflammatory arthritis